Cellular protection through PPAR nuclear receptor activation
Cellular protection through PPAR nuclear receptor activation
复制标题
DOI：
10.2515/therapie:2004006
复制
发表时间：
2004-01-01
期刊：
影响因子：
2.6
通讯作者：
Deplanque, D
中科院分区：
文献类型：
--
作者：
Deplanque, D
除了对脂质和葡萄糖代谢的影响外，核受体PPAR(过氧体增殖物激活受体)也可能参与细胞保护。事实上，越来越多的文献支持PPARα(非诺贝特、吉非贝齐)和PPARγ(环格列酮、吡格列酮、罗格列酮、曲格列酮)激动剂的保护作用，特别是在心肌或脑缺血以及神经退行性疾病中。这种细胞保护可能是在分子水平上调节炎症途径、氧化应激和细胞凋亡的结果。如果这些实验结果被适当的临床试验所证实，核受体PPAR的药理调节，以及开发高选择性和更有效的PPAR激动剂，可能成为细胞保护领域的重要挑战。
Apart from their effects on lipid and glucose metabolism, the nuclear receptors PPARs (peroxysome proliferator- activated receptors) could also be involved in cellular protection. Indeed, an increasing body of literature provides arguments in favour of a protective role of PPARalpha (fenofibrate, gemfibrozil) and PPARgamma (ciglitazone, pioglitazone, rosiglitazone, troglitazone) agonists, particularly in myocardial or cerebral ischaemia as well as in neurodegenerative diseases. Such cellular protection could be the result of the modulation, at a molecular level, of inflammation pathways, oxidative stress and apoptosis. If these experimental results are confirmed by appropriate clinical trials, pharmacological modulation of the nuclear receptor PPARs, as well as the development of highly selective and more effective PPAR agonists, could become an important challenge in the field of cellular protection.